The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation

Brain

Volumn 123, Issue 7, 2000, Pages 1495-1504

  Adams, David ^a   Samuel, Didier ^b   Goulon Goeau, Catherine ^a   Nakazato, Masamitsu ^c   Costa, Paulo M P ^d   Feray, Cyril ^b   Planté, Violaine ^a   Ducot, Béatrice ^a   Ichai, Philippe ^b   Lacroix, Catherine ^a   Metral, Stephane ^a   Bismuth, Henri ^b   Said, Gérard ^a  

^a BICÊTRE HOSPITAL   (France)

^b HÔPITAL PAUL BROUSSE   (France)

^c UNIVERSITY OF MIYAZAKI   (Japan)

^d Centro de Estudos de Paramyloidosis   (Portugal)

Author keywords

Course; Familial amyloid polyneuropathy; Liver transplantation; Transthyretin mutation

Indexed keywords

PREALBUMIN;

ADULT; AGED; AMYLOID NEUROPATHY; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; DYSAUTONOMIA; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; LIVER TRANSPLANTATION; MALE; MOTOR ACTIVITY; MYELINATED NERVE; NERVE BIOPSY; PRIORITY JOURNAL; PROGNOSIS; SENSORIMOTOR NEUROPATHY; SURVIVAL RATE; URINE INCONTINENCE;

EID: 0033919415     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/123.7.1495     Document Type: Article

References (27)

1. Andersson R. Familial amyloidosis with polyneuropathy: a clinical study based on patients living in northern Sweden. Acta Med Scand 1976; Suppl 590.
2. Ando Y, Ando E, Tanaka Y, Yamashita T, Tashima K, Suga M, et al. De novo amyloid synthesis in ocular tissue in familial amyloidotic polyneuropathy after liver transplantation [letter]. Transplantation 1996; 62: 1037-8.
3. Andrade C. A peculiar form of peripheral neuropathy. Brain 1952; 75: 408-27.
4. Araki S, Kurihara T, Tawara S, Kuribayashi T. Familial amyloidotic polyneuropathy in Japanese. In: Glenner GG, Pinho e Costa P, Falcao de Freitas A, editors. Amyloid and amyloidosis. Amsterdam: Excerpta Medica; 1980. p. 67-77.
5. Bergethon PR, Sabin TD, Lewis D, Simms RW, Cohen AS, Skinner M. Improvement in the polyneuropathy associated with familial amyloid polyneuropathy after liver transplantation. Neurology 1996; 47: 944-51.
6. Bismuth H, Farges O, Castaing D, Samuel D, Adam R, Johann M, et al. Evaluation des résultats de la transplantation hépatique: expérience sur une série de 1052 transplantations. Presse Med 1995; 24: 1106-14.
7. Cavallaro T, Martone RL, Dwork AJ, Schon EA, Herbert J. The retinal pigment epithelium is the unique site of transthyretin synthesis in the rat eye. Invest Ophthalmol Vis Sci 1990; 31: 497-501.
8. Consensus statement on indications for liver transplantation: Paris, June 22-23, 1993. [Review]. Hepatology 1994; 20: 63S-68S.
9. Costa PM, Teixeira A, Saraiva MJ, Costa PP. Immunoassay for transthyretin variants associated with amyloid neuropathy. Scand J Immunol 1993; 38: 177-82.
10. Coutinho P, Martins da Silva A, Lopes Lima J, Resende Barbosa A. Forty years of experience with type I amyloid neuropathy. Review of 483 cases. In: Glenner GG, Pinho e Costa P, Falcao de Freitas A, editors. Amyloid and amyloidosis. Amsterdam: Excerpta Medica; 1980. p. 88-98.
11. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972; 34: 187-220.
12. Dubrey SW, Davidoff R, Skinner M, Bergethon P, Lewis D, Falk RH. Progression of ventricular wall thickening after liver transplantation for familial amyloidosis. Transplantation 1997; 64: 74-80.
13. Garcia-Herola A, Prieto M, Pascual S, Berenguer M, Lopez-Viedma B, Mir J, et al. Progression of cardiomyopathy and neuropathy after liver transplantation in a patient with familial amyloidotic polyneuropathy caused by tyrosine-77 transthyretin variant. Liver Transpl Surg 1999; 5: 246-8.
14. Gugenheim J, Samuel D, Saliba F, Castaing D, Bismuth H. Use of flexible triple-drug immunosuppressive therapy in liver transplantation. Transplant Proc 1987; 19: 3805-7.
15. 30). Clin Genet 1991; 40: 242-6.
16. Holmgren G, Ericzon BG, Groth CG, Steen L, Suhr O, Andersen O, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993; 341: 1113-6.
17. Jacobsson B. In situ localization of transthyretin-mRNA in the adult human liver, choroid plexus and pancreatic islets and in endocrine tumours of the pancreas and gut. Histochemistry 1989; 91: 299-304.
18. Lacomblez L, Bouche P, Bensimon G, Meininger V. A double-blind, placebo-controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis. Neurology 1989; 39: 1635-7.
19. Nakazato M, Kangawa K, Minamito N, Tawara S, Matsuo H, Araki S. Radioimmunoassay for detecting abnormal prealbumin in the serum for diagnosis of familial amyloidotic polyneuropathy (Japanese type). Biochem Biophys Res Commun 1984; 122: 719-25.
20. Parrilla P, Ramirez P, Andreu LF, Bueno SF, Robles R, Miras M, et al. Long-term results of liver transplantation in familial amyloidotic polyneuropathy type I. Transplantation 1997; 64: 646-9.
21. Planté-Bordeneuve V, Lalu T, Misrahi M, Reilly MM, Adams D, Lacroix C, et al. Genotypic-phenotypic variations in a series of 65 patients with familial amyloid polyneuropathy. Neurology 1998; 51: 708-14.
22. Said G, Ropert A, Faux N. Length-dependent degeneration of fibers in Portuguese amyloid polyneuropathy: a clinicopathologic study. Neurology 1984; 34: 1025-32.
23. Saraiva MJ. Transthyretin mutations in health and disease. [Review]. Hum Mutat 1995; 5: 191-6.
24. Sobue G, Nakao N, Murakami K, Yasuda T, Sahashi K, Mitsuma T, et al. Type I familial amyloid polyneuropathy: a pathological study of the peripheral nervous system. Brain 1990; 113: 903-19.
25. Soprano DR, Herbert J, Soprano KJ, Schon EA, Goodman DS. Demonstration of transthyretin mRNA in the brain and other extrahepatic tissues in the rat. J Biol Chem 1985; 260: 11793-8.
26. Steen L, Holmgren G, Suhr O, Wikstrom L, Groth CG, Ericzon BG. World-wide survey of liver transplantation in patients with familial amyloidotic polyneuropathy. Amyloid 1994; 1: 138-42.
27. Suhr OB, Holmgren G, Steen L, Wikstrom L, Norden G, Friman S, et al. Liver transplantation in familial amyloidotic polyneuropathy. Transplantation 1995; 60: 933-8.